Mark A. Reed

537 total citations
35 papers, 325 citations indexed

About

Mark A. Reed is a scholar working on Organic Chemistry, Molecular Biology and Biological Psychiatry. According to data from OpenAlex, Mark A. Reed has authored 35 papers receiving a total of 325 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Organic Chemistry, 10 papers in Molecular Biology and 5 papers in Biological Psychiatry. Recurrent topics in Mark A. Reed's work include Tryptophan and brain disorders (5 papers), Alzheimer's disease research and treatments (4 papers) and Catalytic C–H Functionalization Methods (3 papers). Mark A. Reed is often cited by papers focused on Tryptophan and brain disorders (5 papers), Alzheimer's disease research and treatments (4 papers) and Catalytic C–H Functionalization Methods (3 papers). Mark A. Reed collaborates with scholars based in Canada, United States and Peru. Mark A. Reed's co-authors include Donald F. Weaver, Victor Snieckus, Christopher Barden, Ross S. Mancini, M. R. Eastwood, H. B. Kedward, А. В. Калинин, Bryan H. Norman, Robin Eastwood and Mayuri Gupta and has published in prestigious journals such as CHEST Journal, Journal of Medicinal Chemistry and The British Journal of Psychiatry.

In The Last Decade

Mark A. Reed

30 papers receiving 313 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark A. Reed Canada	11	100	53	49	36	32	35	325
Philippe N. Bolduc United States	8	153 1.5×	47 0.9×	48 1.0×	60 1.7×	42 1.3×	14	423
Hildegard Boss Netherlands	14	83 0.8×	78 1.5×	60 1.2×	19 0.5×	15 0.5×	28	416
Sarah Coggan Australia	7	25 0.3×	61 1.2×	101 2.1×	13 0.4×	28 0.9×	11	415
Himani Sharma India	10	50 0.5×	100 1.9×	23 0.5×	11 0.3×	19 0.6×	32	468
Charles Masaki United States	9	46 0.5×	38 0.7×	46 0.9×	33 0.9×	15 0.5×	14	314
Shuhei Yamaguchi Japan	11	35 0.3×	43 0.8×	36 0.7×	86 2.4×	53 1.7×	27	370
Nicholas C. Firth United Kingdom	10	38 0.4×	117 2.2×	100 2.0×	61 1.7×	50 1.6×	15	429
Yuntae Kim South Korea	8	104 1.0×	48 0.9×	15 0.3×	19 0.5×	10 0.3×	31	283
M.W.E. Langemeijer Netherlands	12	16 0.2×	134 2.5×	46 0.9×	26 0.7×	18 0.6×	21	396
Deborah Barlow United States	14	16 0.2×	176 3.3×	35 0.7×	12 0.3×	61 1.9×	26	546

Countries citing papers authored by Mark A. Reed

Since Specialization

Citations

This map shows the geographic impact of Mark A. Reed's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark A. Reed with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark A. Reed more than expected).

Fields of papers citing papers by Mark A. Reed

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark A. Reed. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark A. Reed. The network helps show where Mark A. Reed may publish in the future.

Co-authorship network of co-authors of Mark A. Reed

This figure shows the co-authorship network connecting the top 25 collaborators of Mark A. Reed. A scholar is included among the top collaborators of Mark A. Reed based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark A. Reed. Mark A. Reed is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Elbaz, Mohamad, Wiebke Schormann, Vincent C.O. Njar, et al.. (2024). Sterol-like drugs potentiate statin-triggered prostate cancer cell death by inhibiting SREBP2 nuclear translocation. Biomedicine & Pharmacotherapy. 177. 116934–116934. 2 indexed citations

Reed, Mark A., et al.. (2024). CONCURRENT MYASTHENIA GRAVIS, MYOCARDITIS, AND MYOSITIS SECONDARY TO IMMUNE CHECKPOINT INHIBITORS. CHEST Journal. 166(4). A2693–A2694.

Stover, Kurt R., et al.. (2024). IDO ‐1 inhibition improves outcome after fluid percussion injury in adult male rats. Journal of Neuroscience Research. 102(5). e25338–e25338. 1 indexed citations

Weaver, Donald F., et al.. (2023). Alzheimer’s Disease as an Autoimmune Disease. Alzheimer s & Dementia. 19(S1). 1 indexed citations

Stover, Kurt R., Sanghyun Lee, Seung‐Pil Yang, et al.. (2023). Development and Optimization of a Target Engagement Model of BrainIDO Inhibition for Alzheimer’s Disease. Current Alzheimer Research. 20(10). 705–714. 2 indexed citations

Reed, Mark A., et al.. (2023). Access to Spiro-oxetane Oxindoles via DBU-Catalyzed Activation of Allenoates. Synfacts. 19(10). 972–972. 1 indexed citations

Weaver, Donald F., et al.. (2022). COVID-19 as a Risk Factor for Alzheimer’s Disease. Journal of Alzheimer s Disease. 91(1). 1–23. 21 indexed citations

Kim, Changmo, Izhar Livne‐Bar, Philip J. Parsons, et al.. (2022). A Stereocontrolled Total Synthesis of Lipoxin B4 and its Biological Activity as a Pro‐Resolving Lipid Mediator of Neuroinflammation. Chemistry - A European Journal. 28(35). e202200360–e202200360. 7 indexed citations

Reed, Mark A., et al.. (2022). Multicomponent Synthesis of Fluorescent Indolizine Tetracycles. Synfacts. 18(4). 362–362. 1 indexed citations

10.

Weaver, Donald F., et al.. (2021). The NLRP3 Inflammasome in the Pathogenesis and Treatment of Alzheimer’s Disease. Journal of Alzheimer s Disease. 84(2). 579–598. 13 indexed citations

11.

Zheng, Yong, Kurt R. Stover, Darapaneni Chandra Mohan, et al.. (2021). A Series of 2‐((1‐Phenyl‐1H‐imidazol‐5‐yl)methyl)‐1H‐indoles as Indoleamine 2,3‐Dioxygenase 1 (IDO1) Inhibitors. ChemMedChem. 16(14). 2195–2205. 8 indexed citations

12.

Reed, Mark A., Paul Richardson, & M. A. Jalil Miah. (2021). Rhodium(III)-Catalyzed Synthesis of Functionalized Dihydrobenzofurans. Synfacts. 17(9). 976–976. 1 indexed citations

13.

Reed, Mark A., et al.. (2020). Imaging and Diagnostic Challenges in a Patient With Refractory Hypoglycemia Caused by Insulinomas Related to Multiple Endocrine Neoplasia Type 1. Cureus. 12(5). e8208–e8208. 3 indexed citations

14.

Wang, Zhiyu, et al.. (2020). Is Inhaled Furosemide a Potential Therapeutic for COVID-19?. The American Journal of the Medical Sciences. 360(3). 216–221. 16 indexed citations

15.

Snieckus, Victor, et al.. (2020). One-Pot Synthesis of 2-Trifluoromethyl-6-azaindoles. Synfacts. 16(7). 778–778. 1 indexed citations

16.

Wang, Zhiyu, Yanfei Wang, Seung‐Pil Yang, et al.. (2020). Small molecule therapeutics for COVID-19: repurposing of inhaled furosemide. PeerJ. 8. e9533–e9533. 31 indexed citations

17.

Weaver, Donald F., Christopher Barden, Mayuri Gupta, et al.. (2020). The in silico search for endogenous anti‐Alzheimer's compounds. Alzheimer s & Dementia. 16(S9). 2 indexed citations

18.

Diez‐Cecilia, Elena, Christopher B. Lavery, Mark A. Reed, et al.. (2015). Diversification of edaravone via palladium-catalyzed hydrazine cross-coupling: Applications against protein misfolding and oligomerization of beta-amyloid. Bioorganic & Medicinal Chemistry Letters. 26(1). 100–104. 10 indexed citations

19.

Henzl, Michael T., Mark A. Reed, & Anmin Tan. (2011). Heightened stability of polcalcin Phl p 7 is correlated with strategic placement of apolar residues. Biophysical Chemistry. 159(1). 110–119. 2 indexed citations

20.

Reed, Mark A., et al.. (2004). Anionic O → α- and β-Vinyl Carbamoyl Translocation of 2-(O-Carbamoyl) Stilbenes. Organic Letters. 6(14). 2297–2300. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact